Perspective from Peter H.R. Green, MD, MD
June 26, 2019
1 min read
Save

ImmusanT discontinues phase 2 trial of celiac disease vaccine

Perspective from Peter H.R. Green, MD, MD
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ImmusanT announced that it will discontinue its phase 2 global study of Nexvax2, a peptide-based immunomodulatory vaccine intended to treat celiac disease, according to a company press release.

Although Nexvax2 has been found to be safe and well-tolerated, an interim analysis demonstrated that the vaccine did not provide statistically meaningful protection from gluten exposure for patients with celiac disease compared with placebo.

When reached for comment, ImmusanT said that it “is continuing to compile and analyze information regarding the outcome of this study and will be providing an update accordingly.”